Biochemical role of pancreatic NMDA receptors in the pathogenesis of carbohydrate metabolism disorders
DOI:
https://doi.org/10.24959/ubphj.20.279Keywords:
type 2 diabetes, insulin resistance, pancreatic NMDA receptors, carbohydrate metabolismAbstract
According to World Health Organization expert estimates, type 2 diabetes mellitus (DM2) remains the most common disease, which characterized by persistent disorders of almost all metabolic links.
Aim. To conduct an analytical review of available literature on the biochemical role of pancreatic NMDA receptors in the pathogenesis of carbohydrate metabolism disorders.
Materials and methods. Open-source analysis of the academic and scientific literature.
Results and discussion. According to the examined data, modulation of the activity of extraneuronal receptors, such as pancreatic NMDA receptors, may affect the regulation of carbohydrate metabolism, in particular glucose-stimulated insulin secretion and blood glucose homeostasis. Therefore, it is considered to be of high relevance to study those drugs that block pancreatic receptors to use them as the basis in the creation of new antidiabetic drugs.
Conclusions. NMDAR antagonists can be considered as new potential antidiabetic drugs that not only normalize blood glucose levels, but also have a protective effect onto islet cells. The use of NMDAR antagonists as adjunctive therapy in diabetes mellitus pharmacological correction regimens may be useful in inhibiting disease progression.References
Marquard, J., Otter, S., Welters, A., Stirban, A., Fischer, A., Eglinger, J. (2015). Characterization of pancreatic NMDA receptors as possible drug targets for diabetes treatment. Nat Med., 21 (4), 363–372. doi: 10.1038/nm.3822.
Hashimoto, K. (2017). The NMDA receptors. Cham : SpringerInternational Publishing.
Soltani, N., Qiu, H., Aleksic, M., Glinka, Y., Zhao, F., Liu, R. et al (2011). GABA exerts protective and regenerative effects on islet beta cells and reverses diabetes. Proc Natl Acad Sci U S A, 108 (28), 11692–11697. doi: 10.1073/pnas.1102715108.
Rodriguez-Diaz, R., Dando, R., Huang, Y. A., Berggren, P. O., Roper, S. D., Caicedo, A. (2012). Real-time detection of acetylcholine release from the human endocrine pancreas. Nat Protoc, 7 (6), 1015–1023. doi: 10.1038/nprot.2012.040.
Konstantinova, I., Nikolova, G., Ohara-Imaizumi, M., Meda, P., Kucera, T., Zarbalis, K. et al. (2007). EphA-Ephrin-A-mediated beta cell communication regulates insulin secretion from pancreatic islets. Cell, 129 (2), 359–370. doi: 10.1016/j.cell.2007.02.044.
Platt, S. R. (2007). The role of glutamate in central nervous system health and disease - a review. Vet J, 173 (2), 278–286. doi: 10.1016/j.tvjl.2005.11.007.
Di Cairano, E. S., Davalli, A. M., Perego, L., Sala, S., Sacchi, V. F., La Rosa, S. et al. (2011). The Glial Glutamate Transporter 1 (GLT1) is expressed by Pancreatic beta-cells and prevents Glutamate-induced beta-cell death. J Biol Chem, 286 (16), 14007–1418. doi: 10.1074/jbc.M110.183517.
Feldmann, N., del Rio, R. M., Gjinovci, A., Tamarit-Rodriguez, J., Wollheim, C. B., Wiederkehr, A. (2011). Reduction of plasma membrane glutamate transport potentiates insulin but not glucagon secretionin pancreatic islet cells. Mol Cell Endocrinol, 338 (1–2), 46–57. doi: 10.1016/j.mce.2011.02.019.
Storto, M., Capobianco, L., Battaglia, G., Molinaro, G., Gradini, R., Riozzi, B. et al. (2006). Insulin secretionis controlled by mGlu5 metabotropic glutamate receptors. Mol Pharmacol, 69 (4), 1234–1241. doi: 10.1124/mol.105.018390.
Otter, S., Lammert, E. (2016). Exciting times for pancreatic islets: Glutamate signaling in endocrine cells. Trends Endocrinol Metabolism, 27 (3), 177–188. doi: 10.1016/j.tem.2015.12.004.
Gheni, G., Ogura, M., Iwasaki, M., Yokoi, N., Minami, K., Nakayama, Y. et al. (2014). Glutamate acts as akey signal linking glucose metabolism to Incretin/cAMP action to amplify insulin secretion. Cell Rep, 9 (2), 661–673. doi: 10.1016/j.celrep.2014.09.030.
Cabrera, O., Jacques-Silva, M. C., Speier, S., Yang, S. N., Kohler, M., Fachado, A. et al. (2008). Glutamate is apositive autocrine signal for glucagon release. Cell Metab, 7 (6), 545–554. doi: 10.1016/j.cmet.2008.03.004.
Omar, B., Sorhede-Winzell, M., Ahren, B. (2014). Conditional glucagon receptor overexpression hasmulti-faceted consequences for beta-cell function. Metabolism, 63 (12), 1568–1576. doi: 10.1016/j.metabol.2014.09.004.
Wu, Z. Y., Zhu, L. J., Zou, N., Bombek, L. K., Shao, C. Y., Wang, N. et al. (2012). AMPA receptors regulateexocytosis and insulin release in pancreatic beta cells. Traffic, 13 (8), 1124–39. doi: 10.1111/j.1600-0854.2012.01373.x.
Hawkins, R. A. (2009). The blood-brain barrier and glutamate. Am J Clin Nutr, 90 (3), 867S–874S. doi: 10.3945/ajcn.2009.27462BB.
Kalia, L. V., Kalia, S. K., Salter, M. W. (2008). NMDA receptors in clinical neurology: excitatory times head. Lancet Neurol, 7 (8), 742–55. doi: 10.1016/S1474-4422(08)70165-0.
Gupta, K., Hardingham, G. E., Chandran, S. (2013). NMDA receptor-dependent glutamate excitotoxicityin human embryonic stem cell-derived neurons. Neurosci Lett, 543, 95–100. doi: 10.1016/j.neulet.2013.03.010.
Lutz, T. A., Meyer, U. (2015). Amylin at the interface between metabolic and neurodegenerative disorders. Front Neurosci, 9, 216. doi: 10.3389/fnins.2015.00216.
Eizirik, D. L., Cardozo, A. K., Cnop, M. (2008). The role for endoplasmic reticulum stress in diabetes mellitus. Endocr Rev, 29 (1), 42–61. doi: 10.1210/er.2007-0015.
Ye, L., Huang, Y., Zhao, L., Li, Y., Sun, L., Zhou, Y. et al. (2013). IL-1beta and TNF-alpha induce neurotoxicity through glutamate production: a potential role for neuronal glutaminase. J Neurochem, 125 (6), 897–908. doi: 10.1111/jnc.12263.
Paoletti, P., Bellone, C., Zhou, Q. (2013). NMDA receptor subunit diversity: impact on receptor properties,synaptic plasticity and disease. Nat Rev Neurosci, 14 (6), 383–400. doi: 10.1038/nrn3504.
Lechin, F., van der Dijs, B., Pardey-Maldonado, B., Rivera, J. E., Lechin, M. E., Baez, S. (2009). Amantadinereduces glucagon and enhances insulin secretion throughout the oral glucose tolerance test: central plus peripheral nervous system mechanisms. Diabetes Metab Syndr Obes, 2, 203–213. doi: 10.2147/dmsott.s7606.
Shen, K. Z., Johnson, S. W. (2010). Ca2+ influx through NMDA-gated channels activates ATP-sensitiveK+ currents through a nitric oxide-cGMP pathway in subthalamic neurons. J Neurosci, 30 (5), 1882–1893. doi: 10.1523/JNEUROSCI.3200-09.2010.
Shen, K. Z., Yakhnitsa, V., Munhall, A. C., Johnson, S. W. (2014). AMP kinase regulates K-ATP currentsevoked by NMDA receptor stimulation in rat subthalamic nucleus neurons. Neuroscience, 274, 138–152. doi: 10.1016/j.neuroscience.2014.05.031.
Donath, M. Y. (2014). Targeting inflammation in the treatment of type 2 diabetes: time to start. Nat Rev Drug Discov, 13 (6), 465–76. doi: 10.1038/nrd4275.
Wollheim, C. B., Maechler, P. (2015). Beta cell glutamate receptor antagonists: novel oral antidiabetic drugs? Nat Med, 21 (4), 310–311. doi: 10.1038/nm.3835.
Marquard, J., Stirban, A., Schliess, F., Sievers, F., Welters, A., Otter, S. et al. (2016). Effects of dextromethorphanas add-on to sitagliptin on blood glucose and serum insulin concentrations inindividuals with type 2 diabetes mellitus: a randomized, placebo-controlled, double-blinded,multiple crossover, single-dose clinical trial. Diabetes Obes Metab, 18 (1), 100–103. doi: 10.1111/dom.12576.
Garnock-Jones, K. P. (2011). Dextromethorphan/quinidine: in pseudobulbar affect. CNS Drugs, 25 (5), 435–445. doi: 10.2165/11207260-000000000-00000.
Dicpinigaitis, P. V. (2015). Clinical perspective - cough: an unmet need. Curr Opin Pharmacol, 22, 24–28. doi: 10.1016/j.coph.2015.03.001.
Werling, L. L., Lauterbach, E. C., Calef, U. (2007). Dextromethorphan as a potential neuroprotective agentwith unique mechanisms of action. Neurologist, 13 (5), 272–93. doi: 10.1097/NRL.0b013e3180f60bd8.
Shin, E. J., Bach, J. H., Lee, S. Y., Kim, J. M., Lee, J., Hong, J. S. et al. (2011). Neuropsychotoxic and neuroprotectivepotentials of dextromethorphan and its analogs. J Pharmacol Sci, 116 (2), 137–148. doi: 10.1254/jphs.11R02CR.
Liu, S. L., Li, Y. H., Shi, G. Y., Tang, S. H., Jiang, S. J., Huang, C. W. et al. (2009). Dextromethorphan reducesoxidative stress and inhibits atherosclerosis and neointima formation in mice. Cardiovasc Res, 82 (1), 161–169. doi: 10.1093/cvr/cvp043.
Wu, T. C., Chao, C. Y., Lin, S. J., Chen, J. W. (2012). Low-dose dextromethorphan, a NADPH oxidase inhibitor,reduces blood pressure and enhances vascular protection in experimental hypertension. PLoS One, 7 (9), 460-467. doi: 10.1371/journal.pone.0046067.
Downloads
Published
Issue
Section
License
Copyright (c) 2020 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
